» Articles » PMID: 33362712

SDF-1α/MicroRNA-134 Axis Regulates Nonfunctioning Pituitary Neuroendocrine Tumor Growth Targeting VEGFA

Overview
Specialty Endocrinology
Date 2020 Dec 28
PMID 33362712
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Nonfunctioning pituitary neuroendocrine tumor (NF-PitNET) is difficult to resect. Except for surgery, there is no effective treatment for NF-PitNET. MicroRNA-134 (miR-134) has been reported to inhibit proliferation and invasion ability of tumor cells. Herein, the mechanism underlying the effect of miR-134 on alleviating NF-PitNET tumor cells growth is explored.

Methods: Mouse pituitary αT3-1 cells were transfected with miR-134 mimics and inhibitor, followed by treatment with stromal cell-derived factor-1α (SDF-1α) . MiR-134 expression level: we used quantitative real-time PCR (qRT-PCR) to detect the expression of miR-134. Cell behavior level: cell viability and invasion ability were assessed using a cell counting kit-8 (CCK8) assay and Transwell invasion assay respectively. Cytomolecular level: tumor cell proliferation was evaluated by Ki-67 staining; propidium iodide (PI) staining analyzed the effect of miR-134 on cell cycle arrest; western blot analysis and immunofluorescence staining evaluated tumor migration and invasive ability. Additionally, we collected 27 NF-PitNET tumor specimens and related clinical data. The specimens were subjected to qRT-PCR to obtain the relative miR-134 expression level of each specimen; linear regression analysis was used to analyze the miR-134 expression level in tumor specimens and the age of the NF-PitNET population, gender, tumor invasion, prognosis, and other indicators.

Results: experiment, miR-134 was observed to significantly inhibit αT3-1 cells proliferation characterized by inhibited cell viability and expressions of vascular endothelial growth factor A (VEGFA) and cell cycle transition from G1 to S phase ( < 0.01). VEGFA was verified as a target of miR-134. Additionally, miR-134-induced inhibition of αT3-1 cell proliferation and invasion was attenuated by SDF-1α and VEGFA overexpression ( < 0.01). In primary NF-PitNET tumor analysis, miR-134 expression level was negatively correlated with tumor invasion ().

Conclusion: The regulation of the SDF-1α/miR-134/VEGFA axis represents a novel mechanism in the pathogenesis of NF-PitNETs and may serve as a potential therapeutic target for the treatment of NF-PitNETs.

Citing Articles

High-Grade Ectopic Pituitary Adenoma within the Cerebellopontine Angle: A Case Report.

Anderson C, Sriram A, Funari A, Hsu K, Yokoda R, Pecorari I J Neurol Surg Rep. 2023; 84(2):e51-e58.

PMID: 37090942 PMC: 10121372. DOI: 10.1055/a-2065-9809.


Regulatory mechanisms of microRNAs in endocrine disorders and their therapeutic potential.

Ledesma-Pacheco S, Uriostegui-Pena A, Rodriguez-Jacinto E, Gomez-Hernandez E, Estrada-Meza C, Banerjee A Front Genet. 2023; 14:1137017.

PMID: 36896239 PMC: 9989203. DOI: 10.3389/fgene.2023.1137017.


Chemokine receptor 7 mediates miRNA-182 to regulate cerebral ischemia/reperfusion injury in rats.

Wang Q, Xu S, Wang B, Qin Y, Ji Y, Yang Q CNS Neurosci Ther. 2022; 29(2):712-726.

PMID: 36523152 PMC: 9873520. DOI: 10.1111/cns.14056.


A Retrospective Trail Investigating Temozolomide Neoadjuvant Chemotherapy Combined with Radiotherapy in Low-Grade Pituitary Tumors.

Cui J, Shen J, Ru X, Tian Z, Duan Z, Chen G J Oncol. 2022; 2022:4618664.

PMID: 35368902 PMC: 8975644. DOI: 10.1155/2022/4618664.


The Emerging Role of Non-Coding RNAs in Pituitary Gland Tumors and Meningioma.

Ghafouri-Fard S, Abak A, Hussen B, Taheri M, Sharifi G Cancers (Basel). 2021; 13(23).

PMID: 34885097 PMC: 8656547. DOI: 10.3390/cancers13235987.

References
1.
Barbieri F, Thellung S, Wurth R, Gatto F, Corsaro A, Villa V . Emerging Targets in Pituitary Adenomas: Role of the CXCL12/CXCR4-R7 System. Int J Endocrinol. 2014; 2014:753524. PMC: 4248486. DOI: 10.1155/2014/753524. View

2.
Chen L, Zhang L, Xian G, Lv Y, Lin Y, Wang Y . 25-Hydroxycholesterol promotes migration and invasion of lung adenocarcinoma cells. Biochem Biophys Res Commun. 2017; 484(4):857-863. DOI: 10.1016/j.bbrc.2017.02.003. View

3.
Claesson-Welsh L, Welsh M . VEGFA and tumour angiogenesis. J Intern Med. 2012; 273(2):114-27. DOI: 10.1111/joim.12019. View

4.
McComb D, Ryan N, Horvath E, Kovacs K . Subclinical adenomas of the human pituitary. New light on old problems. Arch Pathol Lab Med. 1983; 107(9):488-91. View

5.
Liang Z, Brooks J, Willard M, Liang K, Yoon Y, Kang S . CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem Biophys Res Commun. 2007; 359(3):716-22. PMC: 1986788. DOI: 10.1016/j.bbrc.2007.05.182. View